Multiplex platform detects co-infections behind similar symptoms, boosting diagnostic accuracy; next-generation respiratory panel data shared at Canadian expert symposium; fully automated AIOS system demonstrated alongside broad test pipeline

Seegene operates an exhibition booth at LMCE 2026, held at the Grand Walkerhill Seoul from Wednesday to Friday, showcasing its comprehensive testing strategy and a range of molecular diagnostic solutions. [Seegene]
Seegene operates an exhibition booth at LMCE 2026, held at the Grand Walkerhill Seoul from Wednesday to Friday, showcasing its comprehensive testing strategy and a range of molecular diagnostic solutions. [Seegene]

Molecular diagnostics company Seegene unveiled a multiplex-based comprehensive testing strategy at an international academic conference, enabling simultaneous detection of multiple pathogens and co-infections in a single test.

Seegene said Monday it participated in the Laboratory Medicine Congress and Exhibition 2026 (LMCE 2026), held at the Grand Walkerhill Seoul from Wednesday to Friday, where it shared its comprehensive infectious disease testing strategy and clinical experience with respiratory panels.

The comprehensive testing approach examines multiple pathogens that cause similar symptoms simultaneously, broadly identifying the causative agent and determining whether co-infections are present.

Respiratory infections are particularly difficult to differentiate because viruses and bacteria can produce nearly identical clinical symptoms, and co-infections involving two or more pathogens are common. Seegene presented a strategy designed to support accurate clinical decision-making, drawing on its technology for simultaneously detecting multiple targets.

At a symposium held as part of the academic program, Dr. Ninad Mehta of Saskatchewan Health Authority in Canada presented early evaluation results for Seegene's next-generation respiratory infection testing panel.

Mehta said syndromic PCR proved valuable in an environment where diverse respiratory viruses and bacteria are circulating simultaneously. He added that the approach yielded clinically meaningful information, including the identification of co-infection cases that had been missed under conventional testing protocols.

On the exhibition floor, Seegene demonstrated the Seegene STARlet-AIOS, its fully automated molecular diagnostics system. The company also showcased test portfolios across multiple disease categories, including respiratory infections, human papillomavirus (HPV), reproductive tract infections, gastrointestinal infections, meningitis and mpox.

In the respiratory segment, Seegene gave particular focus to upcoming products — an Allplex respiratory virus and bacteria panel covering three viral and bacterial targets, and a research-use-only Novaplex avian influenza panel for H5N1, H7 and H9 subtypes — as part of its broader diagnostic portfolio.

Seegene said it aims to move beyond the limitations of single-pathogen testing by standardizing a syndromic diagnostic framework that traces all potential causative agents based on patient symptoms, with the goal of reducing misdiagnosis rates, cutting unnecessary antibiotic prescriptions and advancing precision treatment.

"Respiratory infections are hard to distinguish by symptoms alone, and the likelihood of co-infection is high, making comprehensive testing essential for early, tailored treatment," said Shin Dae-ho, Seegene's executive vice president of global sales and marketing. "We will actively expand the clinical application of comprehensive testing through multiplex-based syndromic PCR and automated systems."


silverpaper@heraldcorp.com